Omicron spike function and neutralizing activity elicited by a comprehensive panel of vaccines
- Autores
- Bowen, John E.; Addetia, Amin; Dang, Ha V.; Stewart, Cameron; Brown, Jack T.; Sharkey, William K.; Sprouse, Kaitlin R.; Walls, Alexandra C.; Mazzitelli, Ignacio Gabriel; Logue, Jennifer K.; Franko, Nicholas M.; Czudnochowski, Nadine; Powell, Abigail E.; Dellota, Exequiel; Ahmed, Kumail; Ansari, Asefa Shariq; Cameroni, Elisabetta; Gori, Andrea; Bandera, Alessandra; Posavad, Christine M.; Dan, Jennifer M.; Zhang, Zeli; Weiskopf, Daniela; Sette, Alessandro; Crotty, Shane; Iqbal, Najeeha Talat; Corti, Davide; Geffner, Jorge Raúl; Snell, Gyorgy; Grifantini, Renata; Chu, Helen Y.; Veesler, David
- Año de publicación
- 2022
- Idioma
- inglés
- Tipo de recurso
- artículo
- Estado
- versión publicada
- Descripción
- The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron variant of concern comprises several sublineages, with BA.2 and BA.2.12.1 having replaced the previously dominant BA.1 and with BA.4 and BA.5 increasing in prevalence worldwide. We show that the large number of Omicron sublineage spike mutations leads to enhanced angiotensin-converting enzyme 2 (ACE2) binding, reduced fusogenicity, and severe dampening of plasma neutralizing activity elicited by infection or seven clinical vaccines relative to the ancestral virus. Administration of a homologous or heterologous booster based on the Wuhan-Hu-1 spike sequence markedly increased neutralizing antibody titers and breadth against BA.1, BA.2, BA.2.12.1, BA.4, and BA.5 across all vaccines evaluated. Our data suggest that although Omicron sublineages evade polyclonal neutralizing antibody responses elicited by primary vaccine series, vaccine boosters may provide sufficient protection against Omicron-induced severe disease.
Fil: Bowen, John E.. University of Washington; Estados Unidos
Fil: Addetia, Amin. University of Washington; Estados Unidos
Fil: Dang, Ha V.. Vir Biotechnology, Inc.; Estados Unidos
Fil: Stewart, Cameron. University of Washington; Estados Unidos
Fil: Brown, Jack T.. University of Washington; Estados Unidos
Fil: Sharkey, William K.. University of Washington; Estados Unidos
Fil: Sprouse, Kaitlin R.. University of Washington; Estados Unidos
Fil: Walls, Alexandra C.. University of Washington; Estados Unidos
Fil: Mazzitelli, Ignacio Gabriel. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Investigaciones Biomédicas en Retrovirus y Sida. Universidad de Buenos Aires. Facultad de Medicina. Instituto de Investigaciones Biomédicas en Retrovirus y Sida; Argentina
Fil: Logue, Jennifer K.. University of Washington; Estados Unidos
Fil: Franko, Nicholas M.. University of Washington; Estados Unidos
Fil: Czudnochowski, Nadine. Vir Biotechnology, Inc.; Estados Unidos
Fil: Powell, Abigail E.. Vir Biotechnology, Inc.; Estados Unidos
Fil: Dellota, Exequiel. Vir Biotechnology, Inc.; Estados Unidos
Fil: Ahmed, Kumail. The Aga Khan University; Pakistán
Fil: Ansari, Asefa Shariq. The Aga Khan University; Pakistán
Fil: Cameroni, Elisabetta. Vir Biotechnology, Inc.; Estados Unidos
Fil: Gori, Andrea. Foundation IRCCS Ca’ Granda Ospedale Maggiore Policlinico; Italia. Università degli Studi di Milano; Italia
Fil: Bandera, Alessandra. Università degli Studi di Milano; Italia. Foundation IRCCS Ca’ Granda Ospedale Maggiore Policlinico; Italia
Fil: Posavad, Christine M.. Fred Hutchinson Cancer Research Center; Estados Unidos
Fil: Dan, Jennifer M.. La Jolla Institute for Allergy and Immunology; Estados Unidos. University of California; Estados Unidos
Fil: Zhang, Zeli. La Jolla Institute for Allergy and Immunology; Estados Unidos
Fil: Weiskopf, Daniela. La Jolla Institute for Allergy and Immunology; Estados Unidos
Fil: Sette, Alessandro. La Jolla Institute for Allergy and Immunology; Estados Unidos. University of California; Estados Unidos
Fil: Crotty, Shane. La Jolla Institute for Allergy and Immunology; Estados Unidos. University of California; Estados Unidos
Fil: Iqbal, Najeeha Talat. The Aga Khan University; Pakistán
Fil: Corti, Davide. Vir Biotechnology, Inc.; Suiza
Fil: Geffner, Jorge Raúl. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Investigaciones Biomédicas en Retrovirus y Sida. Universidad de Buenos Aires. Facultad de Medicina. Instituto de Investigaciones Biomédicas en Retrovirus y Sida; Argentina
Fil: Snell, Gyorgy. Vir Biotechnology, Inc.; Estados Unidos
Fil: Grifantini, Renata. Istituto Nazionale Genetica Molecolare “Romeo ed Enrica Invernizzi"; Italia
Fil: Chu, Helen Y.. University of Washington; Estados Unidos
Fil: Veesler, David. University of Washington; Estados Unidos - Materia
-
SARS-CoV-2
Antibodies
COVID-19 - Nivel de accesibilidad
- acceso abierto
- Condiciones de uso
- https://creativecommons.org/licenses/by/2.5/ar/
- Repositorio
.jpg)
- Institución
- Consejo Nacional de Investigaciones Científicas y Técnicas
- OAI Identificador
- oai:ri.conicet.gov.ar:11336/230550
Ver los metadatos del registro completo
| id |
CONICETDig_8f04dc464f47a2edc5d716d396467bfd |
|---|---|
| oai_identifier_str |
oai:ri.conicet.gov.ar:11336/230550 |
| network_acronym_str |
CONICETDig |
| repository_id_str |
3498 |
| network_name_str |
CONICET Digital (CONICET) |
| spelling |
Omicron spike function and neutralizing activity elicited by a comprehensive panel of vaccinesBowen, John E.Addetia, AminDang, Ha V.Stewart, CameronBrown, Jack T.Sharkey, William K.Sprouse, Kaitlin R.Walls, Alexandra C.Mazzitelli, Ignacio GabrielLogue, Jennifer K.Franko, Nicholas M.Czudnochowski, NadinePowell, Abigail E.Dellota, ExequielAhmed, KumailAnsari, Asefa ShariqCameroni, ElisabettaGori, AndreaBandera, AlessandraPosavad, Christine M.Dan, Jennifer M.Zhang, ZeliWeiskopf, DanielaSette, AlessandroCrotty, ShaneIqbal, Najeeha TalatCorti, DavideGeffner, Jorge RaúlSnell, GyorgyGrifantini, RenataChu, Helen Y.Veesler, DavidSARS-CoV-2AntibodiesCOVID-19https://purl.org/becyt/ford/3.1https://purl.org/becyt/ford/3The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron variant of concern comprises several sublineages, with BA.2 and BA.2.12.1 having replaced the previously dominant BA.1 and with BA.4 and BA.5 increasing in prevalence worldwide. We show that the large number of Omicron sublineage spike mutations leads to enhanced angiotensin-converting enzyme 2 (ACE2) binding, reduced fusogenicity, and severe dampening of plasma neutralizing activity elicited by infection or seven clinical vaccines relative to the ancestral virus. Administration of a homologous or heterologous booster based on the Wuhan-Hu-1 spike sequence markedly increased neutralizing antibody titers and breadth against BA.1, BA.2, BA.2.12.1, BA.4, and BA.5 across all vaccines evaluated. Our data suggest that although Omicron sublineages evade polyclonal neutralizing antibody responses elicited by primary vaccine series, vaccine boosters may provide sufficient protection against Omicron-induced severe disease.Fil: Bowen, John E.. University of Washington; Estados UnidosFil: Addetia, Amin. University of Washington; Estados UnidosFil: Dang, Ha V.. Vir Biotechnology, Inc.; Estados UnidosFil: Stewart, Cameron. University of Washington; Estados UnidosFil: Brown, Jack T.. University of Washington; Estados UnidosFil: Sharkey, William K.. University of Washington; Estados UnidosFil: Sprouse, Kaitlin R.. University of Washington; Estados UnidosFil: Walls, Alexandra C.. University of Washington; Estados UnidosFil: Mazzitelli, Ignacio Gabriel. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Investigaciones Biomédicas en Retrovirus y Sida. Universidad de Buenos Aires. Facultad de Medicina. Instituto de Investigaciones Biomédicas en Retrovirus y Sida; ArgentinaFil: Logue, Jennifer K.. University of Washington; Estados UnidosFil: Franko, Nicholas M.. University of Washington; Estados UnidosFil: Czudnochowski, Nadine. Vir Biotechnology, Inc.; Estados UnidosFil: Powell, Abigail E.. Vir Biotechnology, Inc.; Estados UnidosFil: Dellota, Exequiel. Vir Biotechnology, Inc.; Estados UnidosFil: Ahmed, Kumail. The Aga Khan University; PakistánFil: Ansari, Asefa Shariq. The Aga Khan University; PakistánFil: Cameroni, Elisabetta. Vir Biotechnology, Inc.; Estados UnidosFil: Gori, Andrea. Foundation IRCCS Ca’ Granda Ospedale Maggiore Policlinico; Italia. Università degli Studi di Milano; ItaliaFil: Bandera, Alessandra. Università degli Studi di Milano; Italia. Foundation IRCCS Ca’ Granda Ospedale Maggiore Policlinico; ItaliaFil: Posavad, Christine M.. Fred Hutchinson Cancer Research Center; Estados UnidosFil: Dan, Jennifer M.. La Jolla Institute for Allergy and Immunology; Estados Unidos. University of California; Estados UnidosFil: Zhang, Zeli. La Jolla Institute for Allergy and Immunology; Estados UnidosFil: Weiskopf, Daniela. La Jolla Institute for Allergy and Immunology; Estados UnidosFil: Sette, Alessandro. La Jolla Institute for Allergy and Immunology; Estados Unidos. University of California; Estados UnidosFil: Crotty, Shane. La Jolla Institute for Allergy and Immunology; Estados Unidos. University of California; Estados UnidosFil: Iqbal, Najeeha Talat. The Aga Khan University; PakistánFil: Corti, Davide. Vir Biotechnology, Inc.; SuizaFil: Geffner, Jorge Raúl. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Investigaciones Biomédicas en Retrovirus y Sida. Universidad de Buenos Aires. Facultad de Medicina. Instituto de Investigaciones Biomédicas en Retrovirus y Sida; ArgentinaFil: Snell, Gyorgy. Vir Biotechnology, Inc.; Estados UnidosFil: Grifantini, Renata. Istituto Nazionale Genetica Molecolare “Romeo ed Enrica Invernizzi"; ItaliaFil: Chu, Helen Y.. University of Washington; Estados UnidosFil: Veesler, David. University of Washington; Estados UnidosAmerican Association for the Advancement of Science2022-08info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfapplication/pdfhttp://hdl.handle.net/11336/230550Bowen, John E.; Addetia, Amin; Dang, Ha V.; Stewart, Cameron; Brown, Jack T.; et al.; Omicron spike function and neutralizing activity elicited by a comprehensive panel of vaccines; American Association for the Advancement of Science; Science; 377; 6608; 8-2022; 890-8940036-80751095-9203CONICET DigitalCONICETenginfo:eu-repo/semantics/altIdentifier/doi/10.1126/science.abq0203info:eu-repo/semantics/altIdentifier/url/https://www.science.org/doi/10.1126/science.abq0203info:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by/2.5/ar/reponame:CONICET Digital (CONICET)instname:Consejo Nacional de Investigaciones Científicas y Técnicas2025-09-03T10:04:52Zoai:ri.conicet.gov.ar:11336/230550instacron:CONICETInstitucionalhttp://ri.conicet.gov.ar/Organismo científico-tecnológicoNo correspondehttp://ri.conicet.gov.ar/oai/requestdasensio@conicet.gov.ar; lcarlino@conicet.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:34982025-09-03 10:04:53.855CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicasfalse |
| dc.title.none.fl_str_mv |
Omicron spike function and neutralizing activity elicited by a comprehensive panel of vaccines |
| title |
Omicron spike function and neutralizing activity elicited by a comprehensive panel of vaccines |
| spellingShingle |
Omicron spike function and neutralizing activity elicited by a comprehensive panel of vaccines Bowen, John E. SARS-CoV-2 Antibodies COVID-19 |
| title_short |
Omicron spike function and neutralizing activity elicited by a comprehensive panel of vaccines |
| title_full |
Omicron spike function and neutralizing activity elicited by a comprehensive panel of vaccines |
| title_fullStr |
Omicron spike function and neutralizing activity elicited by a comprehensive panel of vaccines |
| title_full_unstemmed |
Omicron spike function and neutralizing activity elicited by a comprehensive panel of vaccines |
| title_sort |
Omicron spike function and neutralizing activity elicited by a comprehensive panel of vaccines |
| dc.creator.none.fl_str_mv |
Bowen, John E. Addetia, Amin Dang, Ha V. Stewart, Cameron Brown, Jack T. Sharkey, William K. Sprouse, Kaitlin R. Walls, Alexandra C. Mazzitelli, Ignacio Gabriel Logue, Jennifer K. Franko, Nicholas M. Czudnochowski, Nadine Powell, Abigail E. Dellota, Exequiel Ahmed, Kumail Ansari, Asefa Shariq Cameroni, Elisabetta Gori, Andrea Bandera, Alessandra Posavad, Christine M. Dan, Jennifer M. Zhang, Zeli Weiskopf, Daniela Sette, Alessandro Crotty, Shane Iqbal, Najeeha Talat Corti, Davide Geffner, Jorge Raúl Snell, Gyorgy Grifantini, Renata Chu, Helen Y. Veesler, David |
| author |
Bowen, John E. |
| author_facet |
Bowen, John E. Addetia, Amin Dang, Ha V. Stewart, Cameron Brown, Jack T. Sharkey, William K. Sprouse, Kaitlin R. Walls, Alexandra C. Mazzitelli, Ignacio Gabriel Logue, Jennifer K. Franko, Nicholas M. Czudnochowski, Nadine Powell, Abigail E. Dellota, Exequiel Ahmed, Kumail Ansari, Asefa Shariq Cameroni, Elisabetta Gori, Andrea Bandera, Alessandra Posavad, Christine M. Dan, Jennifer M. Zhang, Zeli Weiskopf, Daniela Sette, Alessandro Crotty, Shane Iqbal, Najeeha Talat Corti, Davide Geffner, Jorge Raúl Snell, Gyorgy Grifantini, Renata Chu, Helen Y. Veesler, David |
| author_role |
author |
| author2 |
Addetia, Amin Dang, Ha V. Stewart, Cameron Brown, Jack T. Sharkey, William K. Sprouse, Kaitlin R. Walls, Alexandra C. Mazzitelli, Ignacio Gabriel Logue, Jennifer K. Franko, Nicholas M. Czudnochowski, Nadine Powell, Abigail E. Dellota, Exequiel Ahmed, Kumail Ansari, Asefa Shariq Cameroni, Elisabetta Gori, Andrea Bandera, Alessandra Posavad, Christine M. Dan, Jennifer M. Zhang, Zeli Weiskopf, Daniela Sette, Alessandro Crotty, Shane Iqbal, Najeeha Talat Corti, Davide Geffner, Jorge Raúl Snell, Gyorgy Grifantini, Renata Chu, Helen Y. Veesler, David |
| author2_role |
author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author |
| dc.subject.none.fl_str_mv |
SARS-CoV-2 Antibodies COVID-19 |
| topic |
SARS-CoV-2 Antibodies COVID-19 |
| purl_subject.fl_str_mv |
https://purl.org/becyt/ford/3.1 https://purl.org/becyt/ford/3 |
| dc.description.none.fl_txt_mv |
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron variant of concern comprises several sublineages, with BA.2 and BA.2.12.1 having replaced the previously dominant BA.1 and with BA.4 and BA.5 increasing in prevalence worldwide. We show that the large number of Omicron sublineage spike mutations leads to enhanced angiotensin-converting enzyme 2 (ACE2) binding, reduced fusogenicity, and severe dampening of plasma neutralizing activity elicited by infection or seven clinical vaccines relative to the ancestral virus. Administration of a homologous or heterologous booster based on the Wuhan-Hu-1 spike sequence markedly increased neutralizing antibody titers and breadth against BA.1, BA.2, BA.2.12.1, BA.4, and BA.5 across all vaccines evaluated. Our data suggest that although Omicron sublineages evade polyclonal neutralizing antibody responses elicited by primary vaccine series, vaccine boosters may provide sufficient protection against Omicron-induced severe disease. Fil: Bowen, John E.. University of Washington; Estados Unidos Fil: Addetia, Amin. University of Washington; Estados Unidos Fil: Dang, Ha V.. Vir Biotechnology, Inc.; Estados Unidos Fil: Stewart, Cameron. University of Washington; Estados Unidos Fil: Brown, Jack T.. University of Washington; Estados Unidos Fil: Sharkey, William K.. University of Washington; Estados Unidos Fil: Sprouse, Kaitlin R.. University of Washington; Estados Unidos Fil: Walls, Alexandra C.. University of Washington; Estados Unidos Fil: Mazzitelli, Ignacio Gabriel. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Investigaciones Biomédicas en Retrovirus y Sida. Universidad de Buenos Aires. Facultad de Medicina. Instituto de Investigaciones Biomédicas en Retrovirus y Sida; Argentina Fil: Logue, Jennifer K.. University of Washington; Estados Unidos Fil: Franko, Nicholas M.. University of Washington; Estados Unidos Fil: Czudnochowski, Nadine. Vir Biotechnology, Inc.; Estados Unidos Fil: Powell, Abigail E.. Vir Biotechnology, Inc.; Estados Unidos Fil: Dellota, Exequiel. Vir Biotechnology, Inc.; Estados Unidos Fil: Ahmed, Kumail. The Aga Khan University; Pakistán Fil: Ansari, Asefa Shariq. The Aga Khan University; Pakistán Fil: Cameroni, Elisabetta. Vir Biotechnology, Inc.; Estados Unidos Fil: Gori, Andrea. Foundation IRCCS Ca’ Granda Ospedale Maggiore Policlinico; Italia. Università degli Studi di Milano; Italia Fil: Bandera, Alessandra. Università degli Studi di Milano; Italia. Foundation IRCCS Ca’ Granda Ospedale Maggiore Policlinico; Italia Fil: Posavad, Christine M.. Fred Hutchinson Cancer Research Center; Estados Unidos Fil: Dan, Jennifer M.. La Jolla Institute for Allergy and Immunology; Estados Unidos. University of California; Estados Unidos Fil: Zhang, Zeli. La Jolla Institute for Allergy and Immunology; Estados Unidos Fil: Weiskopf, Daniela. La Jolla Institute for Allergy and Immunology; Estados Unidos Fil: Sette, Alessandro. La Jolla Institute for Allergy and Immunology; Estados Unidos. University of California; Estados Unidos Fil: Crotty, Shane. La Jolla Institute for Allergy and Immunology; Estados Unidos. University of California; Estados Unidos Fil: Iqbal, Najeeha Talat. The Aga Khan University; Pakistán Fil: Corti, Davide. Vir Biotechnology, Inc.; Suiza Fil: Geffner, Jorge Raúl. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Investigaciones Biomédicas en Retrovirus y Sida. Universidad de Buenos Aires. Facultad de Medicina. Instituto de Investigaciones Biomédicas en Retrovirus y Sida; Argentina Fil: Snell, Gyorgy. Vir Biotechnology, Inc.; Estados Unidos Fil: Grifantini, Renata. Istituto Nazionale Genetica Molecolare “Romeo ed Enrica Invernizzi"; Italia Fil: Chu, Helen Y.. University of Washington; Estados Unidos Fil: Veesler, David. University of Washington; Estados Unidos |
| description |
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron variant of concern comprises several sublineages, with BA.2 and BA.2.12.1 having replaced the previously dominant BA.1 and with BA.4 and BA.5 increasing in prevalence worldwide. We show that the large number of Omicron sublineage spike mutations leads to enhanced angiotensin-converting enzyme 2 (ACE2) binding, reduced fusogenicity, and severe dampening of plasma neutralizing activity elicited by infection or seven clinical vaccines relative to the ancestral virus. Administration of a homologous or heterologous booster based on the Wuhan-Hu-1 spike sequence markedly increased neutralizing antibody titers and breadth against BA.1, BA.2, BA.2.12.1, BA.4, and BA.5 across all vaccines evaluated. Our data suggest that although Omicron sublineages evade polyclonal neutralizing antibody responses elicited by primary vaccine series, vaccine boosters may provide sufficient protection against Omicron-induced severe disease. |
| publishDate |
2022 |
| dc.date.none.fl_str_mv |
2022-08 |
| dc.type.none.fl_str_mv |
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion http://purl.org/coar/resource_type/c_6501 info:ar-repo/semantics/articulo |
| format |
article |
| status_str |
publishedVersion |
| dc.identifier.none.fl_str_mv |
http://hdl.handle.net/11336/230550 Bowen, John E.; Addetia, Amin; Dang, Ha V.; Stewart, Cameron; Brown, Jack T.; et al.; Omicron spike function and neutralizing activity elicited by a comprehensive panel of vaccines; American Association for the Advancement of Science; Science; 377; 6608; 8-2022; 890-894 0036-8075 1095-9203 CONICET Digital CONICET |
| url |
http://hdl.handle.net/11336/230550 |
| identifier_str_mv |
Bowen, John E.; Addetia, Amin; Dang, Ha V.; Stewart, Cameron; Brown, Jack T.; et al.; Omicron spike function and neutralizing activity elicited by a comprehensive panel of vaccines; American Association for the Advancement of Science; Science; 377; 6608; 8-2022; 890-894 0036-8075 1095-9203 CONICET Digital CONICET |
| dc.language.none.fl_str_mv |
eng |
| language |
eng |
| dc.relation.none.fl_str_mv |
info:eu-repo/semantics/altIdentifier/doi/10.1126/science.abq0203 info:eu-repo/semantics/altIdentifier/url/https://www.science.org/doi/10.1126/science.abq0203 |
| dc.rights.none.fl_str_mv |
info:eu-repo/semantics/openAccess https://creativecommons.org/licenses/by/2.5/ar/ |
| eu_rights_str_mv |
openAccess |
| rights_invalid_str_mv |
https://creativecommons.org/licenses/by/2.5/ar/ |
| dc.format.none.fl_str_mv |
application/pdf application/pdf |
| dc.publisher.none.fl_str_mv |
American Association for the Advancement of Science |
| publisher.none.fl_str_mv |
American Association for the Advancement of Science |
| dc.source.none.fl_str_mv |
reponame:CONICET Digital (CONICET) instname:Consejo Nacional de Investigaciones Científicas y Técnicas |
| reponame_str |
CONICET Digital (CONICET) |
| collection |
CONICET Digital (CONICET) |
| instname_str |
Consejo Nacional de Investigaciones Científicas y Técnicas |
| repository.name.fl_str_mv |
CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicas |
| repository.mail.fl_str_mv |
dasensio@conicet.gov.ar; lcarlino@conicet.gov.ar |
| _version_ |
1842269880753061888 |
| score |
13.13397 |